Topical ocular sodium 4-phenylbutyrate (PBA) treatment rescued glaucoma phenotypes in a transgenic mouse model of POAG caused by the Y437H MYOC mutation (Tg-MYOCY437H). The gene discussed is MYOC; the disease is glaucoma.